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Abstract 
Alternative splicing of mRNA precursors enables cells to generate different protein 
outputs from the same gene depending on their developmental or homeostatic status. Its 
deregulation is strongly linked to disease onset and progression. Current methodologies 
for monitoring alternative splicing demand elaborate procedures and often present 
difficulties in discerning between closely related isoforms, e.g. due to cross-
hybridization during their detection. Herein, we report a general methodology using a 
Surface Plasmon Resonance (SPR) biosensor for label-free monitoring of alternative 
splicing events in real-time, without any cDNA synthesis or PCR amplification 
requirements. We applied this methodology to RNA isolated from HeLa cells for the 
quantification of alternatively spliced isoforms of the Fas gene, involved in cancer 
progression through regulation of programmed cell death. We demonstrate that our 
methodology is isoform-specific, with virtually no cross-hybridization, achieving limits 
of detection (LODs) in the picoMolar (pM) range. Similar results were obtained for the 
detection of the BCL-X gene mRNA isoforms. The results were independently validated 
by RT-qPCR, with excellent concordance in the determination of isoform ratios. The 
simplicity and robustness of this biosensor technology can greatly facilitate the 
exploration of alternative splicing biomarkers in disease diagnosis and therapy.  
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1. Introduction 
Alternative splicing is a complex process that allows the generation of protein variants 
from a limited repertoire of protein-coding genes in eukaryotic organisms 
(Braunschweig et al. 2013; Nilsen and Graveley 2010).  In this process, primary 
transcripts contain regions (exons) that eventually become part of the mature mRNAs, 
while other intervening sequences (introns) are removed by the process of pre-mRNA 
splicing. However, depending on the way and the number of exons that are combined in 
the final transcript, different alternatively spliced mRNAs outputs, and therefore 
proteins, can be generated, a phenomenon observed in more than 90% of human genes 
(Pan et al. 2008; Wang and et al. 2008). By selecting different exon combinations, the 
mechanism of alternative splicing equips the cells with ways to regulate gene 
expression in order to meet their requirements. Most human genes are alternatively 
spliced to generate from 5-7 isoforms, producing in some cases up to tens of thousands 
of variants (Lee and Rio 2015; Nilsen and Graveley 2010). Likewise, alterations in 
alternative splicing decisions can trigger the onset or influence the progression of many 
diseases, including cancer (Ghigna et al. 2008; Padgett 2012; Tazi et al. 2009). Cancer 
cells can remodel their proteome producing those proteins that best fuel growth and 
spreading of tumors by inducing alternative splicing changes, e.g. in genes that are 
involved in metabolism, apoptosis, cell cycle control, invasion, metastasis, or 
angiogenesis (David and Manley 2010). A clear example is the Fas gene (Izquierdo et 
al. 2005). Alternative splicing of Fas exon 6 generates two isoforms corresponding to 
the inclusion (567 isoform) or skipping (57 isoform) of this exon (Fig. 1). The pro-
apoptotic 567 isoform encodes for a full-length transmembrane protein receptor known 
as APO-1 (or CD95) that binds to Fas ligand (FasL), therefore activating the 
characteristic signaling cascade of the extrinsic apoptotic pathway (Krammer 2000). 
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Exon 6 skipping generates an anti-apoptotic isoform that lacks the trans-membrane 
domain, producing a soluble protein known as sFas that acts as a decoy in the extra-
cellular environment by binding to FasL. This version of Fas, which is overexpressed in 
cancer cells (Cascino et al. 1995; Cheng et al. 1994), contributes to cancer 
aggressiveness (Owen-Schaub et al. 2000; Owen-Schaub et al. 1998) and its detection 
has been proposed as a potential biomarker for the early diagnosis of cancer 
(Boroumand-Noughabi et al. 2010). Therefore, deregulated alternative splicing patterns 
could be considered as a hallmark of cancer and the identification of alternatively 
spliced variants as biomarkers could cast light on cancer development (Oltean and Bates 
2014). Moreover, modulation of splicing isoforms can be considered as a potential 
therapeutic approach. Consequently, monitoring of alternative splicing can offer cues 
for cancer diagnosis and medical care by developing approaches aimed at detecting and 
eventually reverting the deregulated patterns of alternative splicing (Spitali and 
Aartsma-Rus 2012). 
 
Fig. 1. Schematic representation of the different RNA and protein isoforms generated 
by alternative splicing of Fas gene/CD95. 
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Current methodologies, such as exon microarrays or RNA-Seq, can be used to analyse 
differences at the exon and/or at transcript variant level, enabling the identification of 
splicing differences between various types of cancer samples. This isoform-level 
profiling is yielding more precise cancer signatures than gene-level expression profiles 
(Zhang et al. 2013). However, microarray-based or RNA-Seq methods are time 
consuming, expensive and complex for clinical purposes. Methods based on 
quantitative reverse-transcriptase PCR (RT-qPCR) using exon-specific or splice-
junction specific primers (Wu et al. 1996) remain the most suitable approaches. 
Nevertheless, despite their widespread use, RT-qPCR-based methods are far from 
fulfilling the needs of routine clinical applications because of the requirement for 
amplification steps and the use of expensive reagents. Moreover, they often exhibit 
complications in discerning between closely related isoforms (i.e. isoforms sharing 
exons or resulting from insertions of a few nucleotides) due to cross-hybridization. 
Alternative splicing isoforms are intrinsically prone to cross-hybridization (i.e. a not 
intended binding between a probe and an off-target transcript) which constitutes one of 
the main sources of systematic error in the study of alternative splicing. The correction 
of probe-level noise due to cross-hybridization is an indispensable requisite (Xing et al. 
2008). Therefore, the avoidance of cross-hybridization significantly increases the 
reliability of experimental data. 
Concerning the analysis of alternative splicing in routine clinical practice, it is necessary 
to develop a robust methodology to accurately evaluate the expression of the isoforms 
with minimal operator training and in an easy-to-perform procedure. Currently, single 
mRNA spliced variants from BRCA1 gene have been identified and quantified in living 
cells (Lee et al. 2014). However, one major drawback of this approach is the 
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requirement of complex and highly specialized optical set-ups and processes that 
hamper its routine use for diagnosis.  
Here, we report a portable Surface Plasmon Resonance (SPR) biosensor for parallel 
monitoring of alternative splicing events in real-time. SPR biosensor offer significant 
advantages over conventional techniques enabling analysis with high sensitivity and 
excellent reproducibility in few minutes. Moreover, it can detect analytes in real time 
avoiding the use of labels or amplification steps. It represents an user-friendly and 
robust analytical tool for the analysis of oligonucleotides in minimally-processed 
samples as previously demonstrated by detection of DNA targets (Li et al. 2007; 
Vaisocherová et al.) with a specificity up to single mismatches (Carrascosa et al. 2009), 
and various RNA types, such as microRNAs (Lee et al. 2008; Nasheri et al. 2011; 
Sipova et al. 2010; Zhou et al. 2011), triplex-forming RNAs (Carrascosa et al. 2012), 
ribosomal-RNA (Joung et al. 2008; Nelson et al. 2002) as well as other RNA sequences 
(Boucard et al. 2006; Mandir et al. 2009; Nair et al. 2000). However, to the best of our 
knowledge, it has never been applied to the direct quantitative analysis of RNA spliced 
variants. Our methodology permits a rapid (< 20 min) and label-free detection of 
splicing variants directly from purified total RNA of cells without either cDNA 
conversion or PCR amplification. In addition, the absence of amplification steps and its 
reproducibility lead to detections with minimized experimental errors, increasing the 
reliability of the technique. With a previous and easy-to-implement fragmentation step, 
we employed this technology to analyze HeLa cell mRNA variants of the Fas gene. 
 
2. Materials and methods 
2.1. Reagents and HeLa cell RNA samples. 
The list of reagents, buffers and solvent used in this work and procedure of preparation of HeLa 
cell RNA samples is provided in the Suplementary material.  
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2.2. SPR biosensor.  
We employed a portable home-made SPR sensor as previously described (Carrascosa et al. 
2012). The SPR biosensor platform is based on Kretschmann configuration, monitoring the 
binding events in real time. A p-polarized light of 670 nm from a laser source is divided in two 
identical beams focused on the crystal-backside of the sensor chip (glass surface coated with 2 
nm of chromium and 45 nm of gold, 10x10x0.3 mm, SSens, Enschede –The Netherlands-). 
Measurements are performed at a fixed angle of incidence. Variations of the refractive index 
(RI) are detected due to the biointeraction events occurring at the sensor surface as changes in 
the reflected light intensity by a multielement photodiode. The flow system consists of two flow 
cells (300 nL each) for independent analysis. The device incorporates all optics, electronics and 
fluidics components necessary to operate autonomously. Sensograms reproduce the binding 
event by monitoring the increase (or decrease in case of unbinding events) of the intensity of the 
reflected light (ΔReflectivity (%), ΔR (%)) vs. time (seconds, s). This change of the intensity of 
the reflected light is directly related to changes in the RI of the dielectric medium caused by 
mass changes on the metallic surface. 
To prevent from RNAse activity during measurements, the microfluidic sensor was cleaned by 
flowing sequentially SDS 0.5%, HCl 0.1 M, EtOH 100% and sterile H2O. All solid materials 
were autoclaved at 121ºC/20 min for plastic and 134ºC/10 min for glass.   
 
2.3. DNA-probes immobilization.  
Prior to DNA-probe immobilization, gold sensor chips were cleaned by consecutive sonication 
cycles (1 min) with solvents of decreasing polarity (i.e. acetone, ethanol and dH2O) previously 
heated up to their boiling point. Then, substrates are dried under nitrogen flux and placed in an 
UV/O3 generator (BioForce Nanosciences, USA) for 20 min. After that, gold sensor chips are 
subsequently rinsed with ethanol and water and dried under nitrogen flux. The gold sensor chip 
is then placed into the SPR device. 
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Formation of mixed self-assembled monolayers (SAMs) of DNA-probe/MCH (1 µM) was 
carried out in-situ on the gold sensor chip by flowing 250 µL of the mix in PB buffer solution at 
a 12 µL/min rate. Different DNA-probe/MCH molar ratios (no MCH, 10:1 and 20:1) were 
employed depending on the experiment carried out. 
 
2.4. Isoforms hybridization and biosensor regeneration.  
Splicing variants detection was performed by injection of the target splicing variant samples 
into the SPR biosensor at a 16 µL/min rate and subsequent hybridization with their 
complementary DNA-probes immobilized on the sensor surface. These samples were dissolved 
in either 5xSSC (0.75 M in NaCl, 0.075 M in sodium citrate) or 3xSSC (0.45 M in NaCl, 0.045 
M in sodium citrate). Different concentrations of Formamide ≥99.5% (Sigma Aldrich, Steinhem 
– Germany-) were used for improving specificity. Isoform-probe interactions were disrupted by 
using a 50% formamide in aqueous solution (Fuchs et al. 2010). Calibration curves were 
obtained for each DNA-probe by obtaining triplicates measurement of different target dilutions 
from standards of known concentration. The mean and the standard deviation (SD) of each 
concentration were plotted versus the target concentration and fitted to a curve. 
 
 
2.5. Data analysis.  
The data were analyzed using Origin 8.0 software (OriginLab, Northampton, MA). The 
experimental detection limit (LOD) was defined as the target concentration giving a ΔR (%) in 
the hybridization signal at least three times higher than that of the standard deviation of the 
DNA/RNA control signal. Limit of quantification (LOQ) was defined as the target 
concentration giving ΔR (%) in the hybridization signal at least ten times higher than that of the 
standard deviation of the DNA control or the RNA control signal. The coefficients of variation 
were obtained as the ratio of the standard deviation to the mean, expressed in percentages 
(%CV). Individual assay variation was calculated after analysis of three replicates of the target 
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at different concentrations. Inter-assays variations were calculated gathering together all three 
replicates from the individual assays obtained from two different operators. Percentages of 
cross-hybridization were calculated by dividing the average signal intensity of the off-targets 
into the average signal intensity of the complementary isoform. Agreement between RT-qPCR 
and SPR was assessed by applying the Bland-Altman model for replicate measurements. 
 
3. Results and discussion 
3.1. Fas gene alternative splicing biosensing: Optimization and assessment 
Our main objective was to develop a general, fast and user-friendly methodology for the 
label-free and PCR-free detection and quantification of alternatively spliced variants in 
real-time. We used a portable custom-designed biosensor device based on Surface 
Plasmon Resonance (SPR) technology (Carrascosa et al. 2012). We chose the well-
characterized alternative splicing of Fas gene as a model system. Since splice-junctions 
(i.e. complementary to exon sequences flanking the splice junction) represent a unique 
sequence feature of each transcript, we designed two DNA-probes specifically matching 
the splice-junctions of each of the Fas gene isoforms. To enable the parallel analysis of 
the isoforms from purified HeLa cell RNA, we biofunctionalized each SPR sensor cell 
with one of the DNA-probes (Fig. 2A). We carefully optimized biofunctionalization and 
detection conditions using ~140-200 nucleotide-length DNA versions of both isoforms, 
i.e. Fas567 and Fas57, containing the exons of interest (exons 5, 6 and 7 in one case, 
exons 5 and 7 in the other) (Table S1). 
In order to ensure and maximize the target capture, we compared mixed solutions of the 
thiol-modified DNA-probes and alkanethiol 6-mercapto-1-hexanol (MCH), a commonly 
used backfiller that acts as a lateral spacer, improving the target accessibility by 
minimizing steric hindrance forces (Carrascosa et al. 2009). We chose three different 
DNA-probe/MCH ratios (zero MCH, 20:1 and 10:1), generating mixed self-assembled 
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monolayers (SAMs) (Sakao et al. 2005) onto the gold sensor surface. Each condition 
was analyzed by serial injections of 50 nM of specific target in 5x saline-sodium citrate 
(5xSSC) hybridization buffer (Carrascosa et al. 2009; Carrascosa et al. 2012). After each 
hybridization event, isoform-probe interactions were disrupted by using a 50% 
formamide aqueous solution (Fuchs et al. 2010) in order to free the DNA-probe for 
replicate measurements with the same biosurface. As shown in Fig. S1A, 20:1 ratio 
remarkably improved the accessibility of the targets to their complementary DNA-
probes, increasing capture efficiency in 70% and 50% for Fas56 and Fas57 capture 
probes respectively. However, they had a notably high cross-hybridization from the non-
specific isoforms, showing percentages of cross-hybridization from the off-target 
transcripts of 169% (Fas567 probe) and 47% (Fas57 probe). The evident preference of 
Fas567 probe for Fas57 isoform over Fas567  isoform at all of the ratios tested made 
indispensable the avoidance of such crosshybridization in order to achieve a specific 
recognition. 
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Fig. 2. SPR methodology for quantitative evaluation of Fas gene alternatively spliced 
mRNA isoforms. (A) Scheme for the label-free and direct detection of alternative 
spliced variants with an SPR biosensor. (B) SPR calibration plots for Fas57 (left) (R
2
= 
0.99) and Fas56 (right) (R
2
=0.99) DNA-probes using the optimized hybridization and 
detection conditions. Solid lines (blue and pink) correspond to the non-linear fit of the 
calibration curves. Red dashed line corresponds to 3xSD SPR noise, which is the limit 
for the minimum signal detectable. All data show mean ± standard deviation (SD) of 
triplicate measurements.  
 
Taking advantage of the capacity of formamide for destabilizing nucleic acid duplexes 
and increasing hybridization stringency (Fuchs et al. 2010) we studied its effect in the 
off-target/probe interaction at different concentrations (from 25% to 65%). The addition 
of formamide had a drastic effect on specificity, leveraging the sensitivity of the specific 
targets compared to the alternative ones in more than 75% (Fig. S1B). It was particularly 
evident with the Fas56 probe, which presented an extensive cross-hybridization of the 
Fas57 isoform in the absence of formamide. Furthermore, there was an increment in the 
target signal, corroborating the enhancing effect of formamide for the hybridization of 
oligonucleotides to their specific DNA-probes in saline solutions (Fuchs et al. 2010).  To 
further improve the specific detection, we carried out a slight adjustment in the saline 
concentration of the hybridization buffer, reducing the cross-hybridization to 
background levels (Fig. S1C). Changes in the ionic strength of the hybridization buffer 
led to an increase in the stringency, decreasing the likelihood of hybridization and thus 
favoring binding of the fully complementary isoforms over non-fully complementary 
ones (Gong and Levicky 2008; Špringer et al. 2010).  
After applying the optimized conditions, we were able to accurately discriminate 
between the different splicing isoforms while retaining high sensitivity. We achieved 
sensitivity levels at the pM-nM range as depicted in the calibration curves (Fig. 2B). 
Cross-hybridization was negligible even at the highest concentration evaluated of non-
cognate transcripts (50 nM). We obtained LODs of 387 pM (R
2 
= 0.99) for isoform 
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Fas57 and 438 pM (R
2
 = 0.99) for Fas567 and limits of quantification (LOQ), i.e. the 
lower limit of quantification, of 1.3 nM and 1.5 nM, respectively.  
 
 
 
3.2. Repeatability and reproducibility 
To demonstrate the robustness of the biosensor methodology, we assessed its 
repeatability and reproducibility, key parameters in the development of a reliable tool 
for analytical purposes. We determined the Coefficient of Variability (CV) of the signal 
for different target concentrations both within the same sensor chip (intra-assay) and 
among different biofunctionalization processes (inter-assay). In addition, we studied the 
variability between two different operators. Table 1 shows the CVs calculated for four 
concentrations (2, 5, 10 and 30 nM) of the isoforms located in the linear range of the 
calibration curves. The intra-assays showed a signal variation well-below the maximum 
variability recommended for analytical methods (~15%) (Wood 1999), with CVs 
between 2-11 %. Target detection maintained a stable response through at least 80 
regeneration cycles with no notable signal loss compared to initial values (3 %CV) (Fig. 
S2). Furthermore, the reproducibility was markedly accurate even when measurements 
were carried out by different operators, obtaining CVs between 5-9 % and LODs with a 
variability of 1-11% in the inter-assay analysis. This statistical analysis proves the 
robustness of the methodology and its potential use in environments such as clinical 
settings, where simple, highly accurate and reproducible approaches are the main 
requirements. In addition, the consistency of these results is a unique advantage of this 
methodology, making it possible to analyze a set of samples with the same sensor-chip, 
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thereby saving time and resources and minimizing the experimental errors that could 
arise from different assays. 
 
 
 
Table 1. Variability of the SPR sensor signals for Fas isoforms intra- and inter-assays 
performed by different operators. All p-values indicated not significant variation 
between the measurements (P>0.05, one-way ANOVA test). 
 
Concentration 
(nM) 
ΔR(%) 
Intra-assay 1
a
 Intra-assay 2
a
 Intra-assay 3
b
 Inter-assay
ab
 
Fas567 isoform Mean±SD1 CV(%) Mean±SD1 CV(%) Mean±SD1 CV(%) Mean±SD2 CV(%) 
2 0.13±0.01 8 0.13±0.01 9 0.14±0.01 4 0.13±0.01 9 
5 0.24±0.01 4 0.20±0.01 6 0.25±0.01 2 0.23±0.02 9 
10 0.38±0.02 4 0.35±0.01 3 0.39±0.02 6 0.38±0.02 6 
30 0.96±0.03 3 0.98±0.05 5 0.99±0.08 8 0.98±0.05 5 
LOD (pM) 438 - 516 - 423 - 459±50 11 
Fas57 isoform Mean±SD1 CV(%) Mean±SD1 CV(%) Mean±SD1 CV(%) Mean±SD2 CV(%) 
2 0.12±0.01 8 0.12±0.02 13 0.15±0.01 8 0.13±0.02 14 
5 0.23±0.02 9 0.19±0.01 5 0.24±0.01 5 0.22±0.03 12 
10 0.37±0.01 2 0.33±0.02 5 0.39±0.03 6 0.36±0.03 9 
30 0.83±0.02 2 0.86±0.05 6 0.85±0.04 4 0.85±0.04 4 
LOD (pM) 387 - 373 - 380 - 380±7 2 
a
Measurements performed by operator 1. 
b
Measurements performed by operator 2. 
1
Mean ± SD of 3 replicates performed in the same biofunctionalized sensor chip. 
2
Mean ± SD of 9 replicates performed in 3 different biofunctionalized sensor chips. 
 
3.3. BCL-X alternative splicing detection 
The development of a robust methodology that ensures the fidelity of specific splicing 
isoform detection with a minimized preset optimization is challenging. Thereby, we tested 
the versatility of our methodology in the detection of alternatively spliced isoforms from 
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the BCL-X gene. Deregulation of BCL-X gene (Lee et al. 2012) alternative splicing is 
involved in cancer development and can have an important impact in therapeutic decisions 
(Akgul et al. 2004). This gene has a three-exon structure and two 5’-alternative splice sites 
in the first coding exon, generating the BCL-XL and BCL-XS mRNA isoforms (Lee et al. 
2012). When the upstream 5’-splice site is used, it generates the BCLXS mRNA isoform, 
leading to a pro-apoptotic transmembrane protein. The use of the downstream 5’ splice site 
leads to production of the anti-apoptotic BCLXL mRNA isoform that encodes a large 
transmembrane protein (BCL-XL) expressed in the mitochondrial membrane.  
To analyze the mRNA expression levels of BCL-XL and BCL-XS isoforms, we followed the 
same SPR methodological approach using specific DNA-probes matching the splice-
junctions (Table S1) and employed the optimized conditions developed for Fas gene 
detection described above. We obtained similar results to Fas gene (Fig. 3), achieving the 
same degree of specificity with near background levels of cross-hybridization. The LODs 
were 356 pM (R
2 
= 0.99) for BCLXL and 155 pM (R
2
 = 0.99) for BCL-XS, with LOQs of 1.2 
nM and 0.5 nM respectively. Variability of the signals was below 15% for all concentration 
measured (Table S2), supporting the robustness of the methodology as an analytical tool 
for monitoring splicing events. Hence, the methodology was easily reproduced with the 
same efficiency, highlighting its potential as a tool for the monitoring of alternative 
splicing events of different genes and within different biological and eventually 
pathological contexts.  
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Fig. 3. SPR calibration plots for the detection of BCL-XL (left) (R
2
= 0.99) and BCL-XS  
(right) (R
2
= 0.99) synthetic isoforms based on the previously optimized detection 
conditions of Fas gene isoforms. Solid lines (blue and pink) correspond to the non-
linear fit of the calibration curves. Red dashed line corresponds to 3xSD SPR noise, 
which is the limit for the minimum signal detectable. All data show mean ± SD of 
triplicate measurements. 
 
 
 
3.4. Experimental validation of Fas alternative splicing with HeLa cells 
To study the feasibility of the methodology in biological samples, we first tested it in 
ideal conditions. We purified total RNA from HeLa cells transfected with a minigene 
expressing Fas genomic sequences between exons 5 and 7 (~2000 nucleotide primary 
trancripts), either alone or co-transfected with a vector expressing the Polypyrimidine-
Tract-Binding protein (PTB). Previous studies show that PTB induces skipping of Fas 
exon 6 acting through an exonic silencer sequence (Izquierdo et al. 2005). While 
expression of the minigene alone leads to preferential accumulation of exon 6-including 
transcripts, co-expression of Fas 567 minigene with PTB leads to higher accumulation 
of transcripts that skip exon 6 (Förch et al. 2000). In this study, mature transcripts from 
the transfected minigene generated Fas isoforms with approximately similar lengths to 
those employed during the optimization. Thus, we quantified the minigene expression in 
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both cell lines by applying the conditions and calibration curves generated during the 
optimization process.  
Samples were diluted in 3xSSC (45% FA) to a final concentration of 20 ng/µL of 
purified total RNA. We used purified total RNA from bacteria (XLI Blue) as a negative 
control and we also evaluated the response of HeLa cells expressing only endogenous 
levels of Fas transcripts. Shifts in isoform ratios were independently evaluated for each 
HeLa cell line by RT-PCR using primers corresponding to the flanking constitutive 
exons and quantification of the amplification products corresponding to the alternative 
transcript after fractionation by polyacrylamide gel electrophoresis or by RT-qPCR 
using isoform-specific primers.  
 
 
Fig. 4. SPR sensograms of the detection of 20 ng/ µL of total HeLa cell RNA for: (A) 
Minigene-expression for both DNA-probes, Fas56 (left) and Fas57 (right) and (B) 
Endogenous expression of these isoforms either with RNA hydrolysis (Δ) and without 
any treatment (0), detected for both DNA-probes, Fas56 (left) and Fas57 (right).  
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As can be observed in both sensograms (Fig. 4A), mRNAs generated by the expression 
of the transfected minigenes were clearly detected by the SPR biosensor. Bacteria RNA 
control samples showed zero ΔR (%) while samples from minigene-tranfected HeLa-
cells presented a ΔR (%) higher than zero for both isoforms, indicating specific detection 
of the Fas isoforms. Isoforms from HeLa cells expressing only endogenous levels of Fas 
transcripts were not detected under these conditions. Expression of the 567 minigene led 
to higher detection levels of Fas567 isoform compared to Fas57 isoform, while co-
expression of the 567 minigene and PTB expression vector led to higher detection of the 
Fas57 isoform compared to the Fas567 isoform, as previously reported (Izquierdo et al. 
2005) and independently validated in these experiments (Fig. S3A). SPR responses were 
converted to quantitative data by their direct interpolation in the calibration curves. 
These values were also corrected with their respective dilution factors with respect to the 
particular total RNA concentration of each sample. SPR quantitative data correlated very 
closely with the quantitative data obtained with RT-qPCR for the minigene products 
(Table 2). Both, RT-qPCR and SPR techniques, showed an exon-skipping shift of 37% 
and 38% respectively after co-expression with PTB. 567/57 ratios were fairly 
comparable between both techniques with values of 2.2 (RT-qPCR) and 2.5 (SPR) for 
Fas567 overexpression and 0.38 (RT-qPCR) and 0.45 (SPR) with PTB co-expression. 
Both techniques showed a high correlation (r
 
= 0.97) and all data was found within the 
limits of agreement (Fig. S5A). We conclude that the SPR biosensor data were fully 
validated by independent quantitative measurements under these ideal conditions. 
 
Table 2. RT-PCR and SPR comparison of the isoform content analysis from HeLa cells 
endogenous expression and minigene-induced overexpression. Isoform concentration in 
nM for SPR was calculated through the calibration curves obtained for each DNA-probe 
according to their ΔRs (%).  
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Sample type 
Fas 
isoform 
Concentration (nM) 567/ 57ratio 
RT-qPCR SPR RT-qPCR SPR 
RNA Fas567 
overexpression 
567 205 240 ± 23
a
 
2.2 2.5 ± 0.3 
57 93 97 ± 23
a
 
RNA Fas567 overexp. + 
PTB 
567 75
 
92 ± 14
a 
0.38
 
0.45 ± 0.06
 
57 199 204 ± 22
a 
Fas endogenous levels 
567 365 
 
262 ± 27
Δ 
17.9  22.9 ± 1.4
 
57 20 
 
12.0 ± 0.8
Δ 
Δ
Mean ± SD of the concentration obtained in SPR from 2 different measurements from 
purified samples of HeLa cell’s total RNA after alkaline hydrolysis. 
a
Mean ± SD of three independent SPR measurements.
 
 
 
The deficient detection of endogenous HeLa cell Fas RNAs was possibly due to the 
much longer length of the Fas transcripts endogenous isoforms. Target sizes is an 
important factor in optical biosensors based on refractive index changes on solid 
surfaces because of the generation of complex secondary structures that can hinder their 
accessibility to the monolayer, as reviewed elsewhere (Šípová and Homola 2013). To 
circumvent this potential problem, we introduced a step of RNA fragmentation before 
the detection of endogenous isoforms by partial hydrolysis of the RNA. Because alkaline 
hydrolysis has been used for different purposes such as the detection of cell-extracted 
16S rRNAs using SPR imaging (Nelson et al. 2002) or as a tool for genome-wide 
mapping of RNA (Wan et al. 2013), we attempted RNA fragmentation using this 
method. The time of hydrolysis was optimized as previously described (Wan et al. 2013) 
to obtain RNA fragments of the desired length (~200nt), evaluated by agarose gel 
electrophoresis (Fig. S4) at 3.5 min of RNA treatment. To monitor the isoform levels, 
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duplicate measurements were carried out in the SPR sensor. Samples were diluted in 
3xSSC (45% FA) to 20 ng/µL of purified total RNA. Isoform concentrations were 
calculated by interpolation of the sensor signal to the calibration curves obtained for 
each DNA-probe. In parallel, RT-PCR assays and agarose gel electrophoresis (Fig. S3B) 
and RT-qPCR (Table 2) were carried out using the same samples for validation of the 
biosensor data. Fig. 4B shows the SPR sensograms obtained after injection of HeLa 
RNA samples for each DNA-probe. As can be seen, endogenous RNAs generated 
readily detectable signals above background, confirming our hypothesis that RNA 
fragmentation can increase the detection signals by SPR. The results of Table 2 show 
that SPR data generated a slight underestimation of isoform concentrations with respect 
to RT-qPCR quantification. This different quantification may be due to incomplete (or 
excessive) cleavage by the fragmentation protocol applied, suggesting that a further 
optimization of the hydrolysis could generate better matches between SPR and RT-
qPCR values. Due to this underestimation, the correlation between both techniques was 
lower in comparison to ideal conditions (r = 0.86) (Fig. S5B). However, 83% of the 
samples tested (5/6) were found within the limits of agreement. Importantly, a 
comparison of the ratios between isoforms revealed comparable values for the two 
techniques, 17.9 for RT-qPCR and 22.9 for SPR. Indeed, isoform ratios showed a very 
significant correlation (r = 0.99) and presented a 100% validation ratio (3/3) between 
both techniques (Fig. S5C). Far from compromising RNA detection by SPR, RNA 
hydrolysis helped to establish a more general methodology for studying alternative 
splicing processes through SPR biosensor by unifying isoform lengths. Although 
incomplete fragmentation led to a slight underestimation of the actual concentration of 
both isoforms compared to RT-qPCR results, a more accurate setting of the 
fragmentation protocol may further improve the quantification. Estimation of the ratio 
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between alternative spliced isoforms is generally a key for assessing splicing 
deregulation, highlighting the methodology as an appropriate tool for disease diagnosis 
or prognosis. Furthermore, this methodology can be easily implemented to more 
advanced label-free optical biosensor platforms which have demonstrated higher 
sensitivity and multiplexing capabilities than SPR biosensors such those based on 
photonic interferometers (Duval et al. 2012), offering a much more detailed information 
and opening the possibility for the development of new tools for diagnosis and follow-up 
therapies.  
 
 
 
4. Conclusions 
We present a methodology for monitoring mRNA isoforms produced by alternative 
splicing events in real-time employing a portable SPR biosensor. It involves minimal 
sample manipulation and avoids the use of labels or pre-amplification steps in contrast with 
the current gold standard RT-qPCR technique which is prone to introduce bias due to the 
cDNA conversion and amplification processes. Our methodology strictly discriminates 
against the non-complementary isoforms in the pM-nM range. It has been proven to be 
easily reproduced with the same efficiency when it is applied to a different gene, 
highlighting its feasibility as a tool for the monitoring of alternative splicing events of 
different genes and within different biological and pathological contexts. This advantage 
reduces greatly the time and material employed during experimental setups and, therefore, 
minimizes the cost. Moreover, it reduces the systematic errors arisen from different probe 
affinities in the amplification process, leading to a more reliable analysis. 
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The feasibility of the methodology was tested in complex RNA mixture purified from 
HeLa cells transfected and not transfected with various DNA expression constructs. Results 
strongly correlated with RT-qPCR data. Additionally, the biosensor can be reused up to 80 
hybridization/regeneration cycles with no apparent signal loss, which demonstrates its 
robustness and reproducibility for long-term use.  
The simplicity of our SPR methodology, along with the label free detection and the 
minimized sample manipulation, makes it really useful for the real-time monitoring of 
splicing events. In our view, these results open the door for this tool to be routinely 
employed for the analysis of alternatively spliced mRNA isoforms as biomarkers for 
diagnosis and patient follow-ups during therapy, providing a more informative, specific and 
accurate analysis.  
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Table 1. Variability of the SPR sensor signals for Fas isoforms intra- and inter-assays 
performed by different operators. All p-values indicated not significant variation 
between the measurements (P>0.05, one-way ANOVA test). 
 
Concentration 
(nM) 
ΔR(%) 
Intra-assay 1
a
 Intra-assay 2
a
 Intra-assay 3
b
 Inter-assay
ab
 
Fas567 
isoform 
Mean±SD
1 
CV(%) Mean±SD
1 
CV(%) Mean±SD
1
 CV(%) Mean±SD
2
 CV(%) 
2 0.13±0.01 8 0.13±0.01 9 0.14±0.01 4 0.13±0.01 9 
5 0.24±0.01 4 0.20±0.01 6 0.25±0.01 2 0.23±0.02 9 
10 0.38±0.02 4 0.35±0.01 3 0.39±0.02 6 0.38±0.02 6 
30 0.96±0.03 3 0.98±0.05 5 0.99±0.08 8 0.98±0.05 5 
LOD (pM) 438 - 516 - 423 - 459±50 11 
Fas57 isoform Mean±SD
1
 CV(%) Mean±SD
1
 CV(%) Mean±SD
1
 CV(%) Mean±SD
2
 CV(%) 
2 0.12±0.01 8 0.12±0.02 13 0.15±0.01 8 0.13±0.02 14 
5 0.23±0.02 9 0.19±0.01 5 0.24±0.01 5 0.22±0.03 12 
10 0.37±0.01 2 0.33±0.02 5 0.39±0.03 6 0.36±0.03 9 
30 0.83±0.02 2 0.86±0.05 6 0.85±0.04 4 0.85±0.04 4 
LOD (pM) 387 - 373 - 380 - 380±7 2 
a
Measurements performed by operator 1. 
b
Measurements performed by operator 2. 
1
Mean ± SD of 3 replicates performed in the same biofunctionalized sensor chip. 
2
Mean ± SD of 9 replicates performed in 3 different biofunctionalized sensor chips. 
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Table 2. RT-PCR and SPR comparison of the isoform content analysis from HeLa cells 
endogenous expression and minigene-induced overexpression. Isoform concentration in 
nM for SPR was calculated through the calibration curves obtained for each DNA-probe 
according to their ΔRs (%).  
 
 
Sample type 
Fas 
isoform 
Concentration (nM) 567/ 57ratio 
RT-qPCR SPR RT-qPCR SPR 
RNA Fas567 
overexpression 
567 204.6 240 ± 23
a
 
2.2 2.5 ± 0.3 
57 93.2 97 ± 23
a
 
RNA Fas567 
overexp. + PTB 
567 74.9
 
92 ± 14
a 
0.38
 
0.45 ± 0.06
 
57 198.8 204 ± 22
a 
Fas endogenous 
levels 
567 365 
 
262 ± 27
Δ 
17.9  22.9 ± 1.4
 
57 20.3 
 
12.0 ± 0.8
Δ 
Δ
Mean ± SD of the concentration obtained in SPR from 2 different measurements 
from purified samples of HeLa cell’s total RNA after alkaline hydrolysis. 
a
Mean ± SD of three independent SPR measurements.
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- A direct and label-free biosensing platform for alternative splicing monitoring is 
reported. 
 
- Total discrimination against non-complementary isoforms was achieved reducing cross-
hybridization to background levels. 
 
- An RNA alkaline hydrolysis stepis performed to improve target accessibility and to 
establish a general methodology. 
 
 
- Versatility of the methodology is demonstrated, being easily reproduced with the same 
efficiency when it is applied to a different gene. 
 
- Results strongly correlated with RT-qPCR data, representing a useful tool for the real-
time monitoring of splicing events 
 
 
  
*Highlights (for review)
